Glow Peptide Blend 70mg — Research Protocol Reference

Glow Blend is administered once daily via subcutaneous injection.

Morning or early evening dosing are both appropriate, the priority is a consistent time held across the full active cycle. No fasting is required.

Do not use if you have Wilson's disease or any known copper metabolism disorder.

Glow Blend is dosed as a single formulation at 20mg/mL (3.5mL BAC)

In biohacking forums, protocols pairing BPC-157 and TB-500 at consistent daily doses for 6–8 week cycles are among the most frequently reported healing stacks.

Glow Blend is injected subcutaneously once daily. Consistency of timing across the full 8-week active cycle matters more than the specific time of day chosen.

• Morning or early evening: Both are appropriate. Pick one and hold it for the entire cycle. Some users prefer morning to align with the body's natural collagen synthesis rhythms; others prefer evening to pair with overnight tissue repair activity. Either approach is documented.
• No food restrictions: Glow Blend does not require fasted administration. Inject before or after meals without affecting activity.
• Inject close to target tissue where possible: BPC-157 produces the strongest localised repair response when injected subcutaneously near the area of concern, skin, joint, or soft tissue. TB-500 is systemic from any injection point and does not require proximity to the target site.
• Rotate injection sites every session: With daily injections across an 8-week cycle, rotate systematically across the abdomen and outer thighs. GHK-Cu is UV-sensitive, avoid prolonged sun exposure to active injection sites and keep the reconstituted vial stored in a dark location or wrapped in foil.
• Complete the full 8-week rest: The rest period is driven primarily by GHK-Cu's copper content. Do not shorten it, the off period is what makes the repeat cycle as effective as the first and allows safe copper clearance.

• One vial, one injection: All three peptides are in a single vial, one draw, one injection delivers the full blend. No need to manage multiple vials or syringes per session.
• Copper accumulation, mandatory rest: GHK-Cu delivers a small copper load with each injection. The 8-week rest period allows your body to clear it through normal copper metabolism. Do not skip or shorten this.
• Effects build on different timelines: BPC-157's anti-inflammatory and angiogenic effects are typically noticeable within 1–2 weeks. TB-500's systemic repair and flexibility improvements emerge across weeks 2–4. GHK-Cu's collagen remodelling effects are the slowest, meaningful skin firmness and texture changes consolidate at weeks 6–8 and continue after the cycle ends.
• Wilson's disease, absolute contraindication: Individuals with Wilson's disease or any inherited copper metabolism disorder must not use this blend.
• Active cancer, do not use: TB-500's angiogenic activity is contraindicated for individuals with active cancer diagnoses.
• Discard at 28–30 days post-reconstitution: Protect from light at all times, GHK-Cu degrades faster than most peptides under UV exposure.

Taking too much Glow Blend can increase side effects. Signs your dose may be too high:

• Injection site redness or swelling beyond 24 hours: Reduce to the intro dose (25 units) and rotate sites more consistently. Persistent local reactions suggest the dose volume at any one site is too high.
• Blood pressure drop or light-headedness: GHK has documented antihypertensive activity. Reduce to 25 units and monitor blood pressure for several days before reassessing.
• Nausea or digestive discomfort: BPC-157 and GHK-Cu both influence gut signalling. Reduce to 25 units/day and hold for one week if discomfort persists beyond 3 days.
• Fatigue or mild headache: Reported with above-range doses of TB-500. Reduce to 25 units and hold for one week before reassessing.
• Signs of copper excess: Persistent nausea, abdominal pain, or metallic taste across multiple days. Discontinue and consult a healthcare professional.

If any of these occur, step back to 25 units/day and hold for one week before attempting to advance again.

A dose may be too low if expected effects are absent after consistent use. Common indicators:

• No reduction in inflammation or localised pain by weeks 2–3: BPC-157's anti-inflammatory effects are typically among the first benefits noticed. Absence after 2–3 weeks at maintenance suggests confirming injection technique and timing before adjusting.
• No improvement in skin firmness or texture by weeks 6–8: GHK-Cu's collagen remodelling timeline is slow. Absence at week 6–8 at full maintenance dose, with consistent daily dosing confirmed, suggests the cycle needs to run its full 8 weeks before reassessing.
• No improvement in range of motion or recovery speed by weeks 4–6: TB-500's flexibility and tissue repair benefits typically consolidate by mid-cycle. Confirm subcutaneous injection technique if absent.

If these indicators persist after a full 8-week cycle, take the full rest period and repeat. GHK-Cu's collagen effects in particular continue developing after the cycle ends, assess final results 4 weeks after completion, not immediately at week 8.

⚠️ This is for informational purposes only. For medical advice or diagnosis, consult a professional. ⚠️